Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Eczema

    Irvine, CA

    Search
    Eczema
    Irvine, CA
    Show Map
    Map View
    Irvine, CA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Clear All

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      51 Eczema Trials near Irvine, CA

      Power is an online platform that helps thousands of Eczema patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Amlitelimab for Eczema

      Santa Ana, California
      This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD). The main objective of this study is to evaluate if those participants who received amlitelimab dose 1 in the parent studies (EFC17559 \[COAST-1\], EFC17560 \[COAST 2\], EFC17561 \[SHORE\]) and were responders can maintain their response either remaining at dose 1 or switching to dose 2 of amlitelimab compared to treatment withdrawal. Study details include: The study duration will be up to 68 weeks including a 52-week randomized double-blind period, and a 16-week safety follow-up for participants not entering the LTS17367 (RIVER-AD). The study duration will be up to 52 weeks for participants entering the LTS17367 \[RIVER-AD\] study at the Week 52 visit of EFC17600 (ESTUARY). The total treatment duration will be up to 52 weeks. The total number of visits will be up to 15 visits (or 14 visits for those entering LTS17367 \[RIVER-AD\] study).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Adverse Events, Non-compliance, Others

      961 Participants Needed

      Nemolizumab for Eczema

      Santa Ana, California
      Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Low Body Weight, Others
      Must Not Be Taking:Antibiotics, Antivirals, Antifungals

      1700 Participants Needed

      CGB-500 Ointment for Eczema

      Santa Ana, California
      The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 improve atopic dermatitis by decreasing the area affected and the severity of the lesions? What medical problems do participants have when taking CGB500? Researchers will compare CGB-500 to a placebo (a look-alike substance that contains no drug) to see if CGB-500 works to treat atopic dermatitis. Participants will: Take CGB-500 or a placebo every day for 8 weeks. Visit the clinic once every 2 weeks for the first month and at the end of 8 weeks. Keep a diary of when they use the product and complete a form about their symptoms including itching.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Immunocompromised, Skin Infections, Others
      Must Not Be Taking:JAK Inhibitors, CYP3A4 Inhibitors

      180 Participants Needed

      UCB1381 for Eczema

      Tustin, California
      This trial is testing a new drug called UCB1381 to see if it is safe and well-tolerated when given through a vein or under the skin. The study includes both healthy individuals and those with atopic dermatitis, a condition causing red, itchy skin. The drug likely works by calming the immune system to reduce skin inflammation.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Inflammatory Bowel Disease, Others
      Must Be Taking:Topical Corticosteroids

      273 Participants Needed

      Abrocitinib for Atopic Dermatitis/Eczema

      Santa Ana, California
      This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Other Skin Diseases, Psychiatric Conditions, Others

      3164 Participants Needed

      Rocatinlimab for Atopic Dermatitis/Eczema

      Tustin, California
      This trial is testing rocatinlimab to see if it is safe and can be tolerated by people with moderate-to-severe eczema. The medication works by calming the immune system to reduce skin inflammation and irritation.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:12 - 100

      Key Eligibility Criteria

      Disqualifiers:Permanent Investigational Product Discontinuation, Others

      2200 Participants Needed

      Rocatinlimab for Eczema

      Irvine, California
      This trial tests the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe atopic dermatitis. Rocatinlimab works by reducing inflammation and calming the immune system.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12 - 17

      Key Eligibility Criteria

      Disqualifiers:Biologics, Corticosteroids, Immunosuppressants, Others
      Must Not Be Taking:Biologics, Corticosteroids, Immunosuppressants, Others

      187 Participants Needed

      Upadacitinib for Eczema

      Santa Ana, California
      This trial is testing upadacitinib, an oral medication, to see if it can help people with severe eczema. The medication works by calming down the overactive immune system to reduce skin inflammation and itching. Upadacitinib is approved in many countries for the treatment of atopic dermatitis in individuals whose disease is not adequately controlled with other treatments or when those treatments are not suitable.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12 - 75

      Key Eligibility Criteria

      Disqualifiers:Other Skin Diseases, Pregnancy, Others
      Must Not Be Taking:JAK Inhibitors

      912 Participants Needed

      Upadacitinib + Topical Corticosteroids for Eczema

      Irvine, California
      The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:12 - 75

      Key Eligibility Criteria

      Disqualifiers:Other Skin Diseases, Pregnancy, Others
      Must Be Taking:Topical Corticosteroids

      1500 Participants Needed

      Lebrikizumab for Eczema

      Santa Ana, California
      This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      1188 Participants Needed

      Lebrikizumab for Eczema

      Santa Ana, California
      This trial is testing lebrikizumab, a medication that reduces inflammation, in adolescents and adults with severe eczema and skin of color. The goal is to see if it is safe and effective for these patients.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      80 Participants Needed

      Lebrikizumab for Atopic Dermatitis

      Fountain Valley, California
      The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with moderate-to-severe atopic dermatitis. This study will last about 68 weeks and may include up to 16 planned visits. If participating in the optional extension as well, the study will last approximately 1 additional year for a total of up to 116 weeks and may include up to 29 scheduled visits.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:6 - 18

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Serious Adverse Events, Others

      310 Participants Needed

      Lebrikizumab for Eczema

      Fountain Valley, California
      The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:6 - 17

      Key Eligibility Criteria

      Disqualifiers:Recent Clinical Study, Others
      Must Not Be Taking:Dupilumab

      360 Participants Needed

      Amlitelimab for Eczema

      Anaheim, California
      This trial is testing amlitelimab, a medication for adults with moderate to severe atopic dermatitis who were in a previous trial. The study aims to see if the medication is safe and effective over an extended time. Amlitelimab works by calming the immune system to reduce skin inflammation.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Immunosuppression, Transplant History, Malignancies, TB, Others

      1551 Participants Needed

      Lebrikizumab for Eczema

      Fountain Valley, California
      The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Allergic Contact Dermatitis, Protein Contact Dermatitis, Others
      Must Not Be Taking:Topical Medications, IL-13 Inhibitors

      206 Participants Needed

      Camoteskimab for Eczema

      Fountain Valley, California
      This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Other Skin Diseases, Severe Comorbidities, Active Infections, Others
      Must Not Be Taking:Biologics, JAK Inhibitors

      60 Participants Needed

      Rezpegaldesleukin for Atopic Dermatitis

      Fountain Valley, California
      This trial tests a modified protein called rezpegaldesleukin in adults with moderate to severe atopic dermatitis. The treatment aims to help the immune system reduce skin inflammation and symptoms.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Other Skin Conditions, Malignancies, Immunosuppression, Others
      Must Not Be Taking:JAK Inhibitors, Biologics

      396 Participants Needed

      Amlitelimab for Atopic Dermatitis/Eczema

      Fountain Valley, California
      This trial tests amlitelimab, a medication that may help adults with moderate-to-severe atopic dermatitis respond better to vaccines. It works by improving how the immune system functions.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Immunosuppression, Malignancies, Active Infections, Others

      215 Participants Needed

      Amlitelimab for Eczema

      Newport Beach, California
      This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD). The purpose of this study is to characterize the long-term safety and efficacy of amlitelimab in treated participants with age ≥12 years old with moderate to severe AD. The study duration per participant will be up to 180 weeks, including: * A screening period of up to 2 to 4 weeks * An open label treatment period of up to 160 weeks (approximately 3 years) * A post-treatment safety follow-up period of at least 20 weeks after the last dose administration The planned number of visits will be 26 visits.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Immunosuppression, Malignancies, Transplant, Others
      Must Not Be Taking:Live Vaccines

      901 Participants Needed

      Nemolizumab for Eczema

      Fountain Valley, California
      This trial is testing nemolizumab, a medication designed to help children with moderate-to-severe eczema. Nemolizumab is a medication developed for treating skin diseases, including severe eczema. The drug works by blocking proteins that cause skin problems and itching. Researchers aim to see how well it works and if it is safe for these children.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:2 - 12

      Key Eligibility Criteria

      Disqualifiers:Chronic Bronchitis, Hepatitis, HIV, Others
      Must Be Taking:Topical Corticosteroids

      105 Participants Needed

      Why Other Patients Applied

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58
      Match to a Eczema Trial

      Ruxolitinib Cream for Hand Eczema

      Huntington Beach, California
      This trial is testing a cream called ruxolitinib for adults with chronic hand eczema that is moderate to severe. The cream works by blocking enzymes that cause inflammation, which may help reduce eczema symptoms. The goal is to see if this treatment is safe and effective for these patients.

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      186 Participants Needed

      Upadacitinib for Eczema

      Mission Viejo, California
      Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD. Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib Dose A or dupilumab Dose A. Based on the participants response to upadacitinib Dose A, they may have their dose increased to upadacitinib Dose B after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult participants ages 18 to 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 94 sites worldwide. The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for 32 weeks and followed for 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 63

      Key Eligibility Criteria

      Disqualifiers:HIV, Active TB, Hepatitis B/C, Others
      Must Be Taking:Dupilumab

      300 Participants Needed

      Ruxolitinib Cream for Eczema

      Fountain Valley, California
      This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Immunocompromised, Hepatitis B/C, HIV, Others
      Must Not Be Taking:Biologics, Systemic Corticosteroids

      241 Participants Needed

      Tralokinumab for Atopic Hand Eczema

      Fountain Valley, California
      The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to 4 weeks. For the first 16 weeks after screening, trial participants will receive either tralokinumab or dummy injections every two weeks. After the first 16 weeks, all trial participants will receive tralokinumab injections every two weeks for 16 weeks. The last part of the trial is a period of 4 weeks after the end of treatment period, where trial participants are off the drug for safety follow-up.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Contact Dermatitis, Phototherapy, Others
      Must Not Be Taking:Immunosuppressives, Corticosteroids, Biologics, Others

      402 Participants Needed

      OpSCF for Eczema

      Fountain Valley, California
      This trial is testing a new medicine called OpSCF for adults with moderate to severe eczema. OpSCF works by blocking proteins that cause skin inflammation. The study will evaluate if OpSCF is effective and safe.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Significant Medical Condition, Others
      Must Not Be Taking:Dupilumab, Tralokinumab

      48 Participants Needed

      APG777 for Eczema

      Fountain Valley, California
      This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Prior APG777 Study, Others
      Must Not Be Taking:Monoclonal Antibodies, Others

      391 Participants Needed

      PF-07832837 for Eczema

      Anaheim, California
      The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Infections, Malignancies, Skin Diseases, Others
      Must Not Be Taking:Antibiotics, Antivirals, Antifungals, Others

      111 Participants Needed

      FB825 for Eczema

      Fountain Valley, California
      This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B/C, Drug Abuse, Others
      Must Be Taking:Emollients

      90 Participants Needed

      Upadacitinib for Eczema

      Newport Beach, California
      The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12 - 75

      Key Eligibility Criteria

      Disqualifiers:Other Skin Diseases, Pregnancy, Others
      Must Not Be Taking:JAK Inhibitors

      912 Participants Needed

      Dupilumab for Eczema

      Orange, California
      The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD. The secondary objectives of the study are: * To assess the long-term efficacy of dupilumab in pediatric participants with AD * To assess the trough concentrations of functional dupilumab in serum and the immunogenicity in pediatric participants with AD after re-treatment with dupilumab Optional Pre-filled Pen (PFP) Sub-Study in pediatric patients ≥2 to \<12 years of age with AD Co-Primary Objectives are: * To evaluate the pharmacokinetic (PK) of dupilumab PFPs * To evaluate the safety of dupilumab PFPs Secondary Objective is: - To evaluate the immunogenicity of dupilumab PFPs
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:6 - 17

      Key Eligibility Criteria

      Disqualifiers:Severe Illness, Endoparasitic Infections, Others
      Must Be Taking:Dupilumab

      880 Participants Needed

      12

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Eczema clinical trials in Irvine, CA pay?
      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
      How do Eczema clinical trials in Irvine, CA work?
      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Eczema trials in Irvine, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Irvine, CA for Eczema is 12 months.
      How do I participate in a study as a "healthy volunteer"?
      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Irvine, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
      What does the "phase" of a clinical trial mean?
      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
      Do I need to be insured to participate in a Eczema medical study in Irvine, CA ?
      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
      What are the newest Eczema clinical trials in Irvine, CA ?
      Most recently, we added Lebrikizumab for Eczema, KT-621 for Eczema and RO7790121 for Eczema to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in California

      Anxiety Clinical Trials in California

      Schizophrenia Clinical Trials in California

      ADHD Clinical Trials in California

      Bipolar Disorder Clinical Trials in California

      Multiple Sclerosis Clinical Trials in California

      Autism Clinical Trials in California

      Treatment Resistant Depression Clinical Trials in California

      Borderline Personality Disorder Clinical Trials in California

      Social Anxiety Disorder Clinical Trials in California

      Parkinson's Disease Clinical Trials in California

      Alzheimer's Disease Clinical Trials in California

      By Location

      Clinical Trials near Los Angeles, CA

      Clinical Trials near San Francisco, CA

      Clinical Trials near San Diego, CA

      Clinical Trials near Sacramento, CA

      Clinical Trials near La Jolla, CA

      Clinical Trials near Orange, CA

      Clinical Trials near Stanford, CA

      Clinical Trials near Palo Alto, CA

      Clinical Trials near Long Beach, CA

      Clinical Trials near Duarte, CA

      Clinical Trials near Oakland, CA

      Clinical Trials near Santa Monica, CA

      Other People Viewed

      By Subject

      Top Clinical Trials near Irvine, CA

      77 Arthritis Trials near Irvine, CA

      Top Schizophrenia Clinical Trials near Irvine, CA

      26 Osteoarthritis Trials near Irvine, CA

      55 Eczema Trials near San Francisco, CA

      Top Eczema Clinical Trials near Los Angeles, CA

      Top Eczema Clinical Trials

      Top Eczema Clinical Trials near Birmingham, AL

      Top Eczema Clinical Trials near Phoenix, AZ

      Top Eczema Clinical Trials near Orlando, FL

      Top Eczema Clinical Trials near Dallas, TX

      Top Eczema Clinical Trials near Alexandria, VA

      By Trial

      Upadacitinib for Eczema

      OPTIMIZE Program for Pregnancy Care

      GSK1070806 for Eczema

      Moisturizer Routine Monitoring for Eczema

      GRIT Intervention for Adverse Childhood Experiences

      Monthly Cash Gifts for Child Development

      SIM0500 for Multiple Myeloma

      Harm Reduction for Smoking in People With HIV

      Digital Therapy Apps for Childhood Behavior Problems

      Aortic Valve-in-Valve for Aortic Stenosis

      Post-Operative Brace for Hip Arthroscopy Recovery

      PTC596 + Radiotherapy for Brain Tumor

      Related Searches

      Top Autism Clinical Trials near Glendale, AZ

      Top Type-2-diabetes Clinical Trials

      Home-Based Exercise Program for Gynecologic Cancer Survivors

      Triheptanoin for MCADD

      Ponsegromab for Heart Failure

      Tako Breath for Takotsubo Syndrome

      Naxitamab for High-Risk Neuroblastoma

      Fulvestrant vs Anastrozole for Breast Cancer

      Auricular Neurostimulation for Traumatic Brain Injury

      4D-ICE + TEE Imaging for Atrial Fibrillation

      ABBV-514 + Budigalimab for Lung & Head and Neck Cancers

      BI 3706674 for Stomach and Esophageal Cancer